AADI - Aadi Bioscience, Inc. Stock Price and Quote

AADI [NASD]

Index	-	P/E	-	EPS (ttm)	-2.98	Insider Own	0.30%	Shs Outstand	21.27M	Perf Week	-2.47%
Market Cap	174.34M	Forward P/E	-	EPS next Y	-2.53	Insider Trans	0.00%	Shs Float	20.64M	Perf Month	-34.95%
Income	-62.60M	PEG	-	EPS next Q	-0.71	Inst Own	63.00%	Short Float / Ratio	7.04% / 10.77	Perf Quarter	-40.90%
Sales	11.00M	P/S	15.85	EPS this Y	-712.40%	Inst Trans	13.63%	Short Interest	1.45M	Perf Half Y	-49.03%
Book/sh	7.95	P/B	0.89	EPS next Y	13.90%	ROA	-40.20%	Target Price	42.50	Perf Year	-60.06%
Cash/sh	7.46	P/C	0.95	EPS next 5Y	-	ROE	-46.50%	52W Range	6.80 - 18.47	Perf YTD	-44.58%
Dividend	-	P/FCF	-	EPS past 5Y	-1.30%	ROI	-77.90%	52W High	-61.51%	Beta	1.28
Dividend %	-	Quick Ratio	10.60	Sales past 5Y	-	Gross Margin	89.90%	52W Low	4.56%	ATR	0.48
Employees	76	Current Ratio	10.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	28.64	Volatility	5.18% 7.21%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	92.60%	Profit Margin	-	Rel Volume	1.85	Prev Close	7.12
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 28 BMO	Payout	-	Avg Volume	134.74K	Price	7.11
Recom	1.60	SMA20	-11.25%	SMA50	-31.95%	SMA200	-42.60%	Volume	243,547	Change	-0.14%

Jan-11-22

Initiated

Jefferies

Buy

$45

Oct-01-21

Initiated

Cowen

Outperform

Sep-14-21

Initiated

Ladenburg Thalmann

Buy

$51

Sep-08-21

Initiated

Piper Sandler

Overweight

$45

Mar-28-23 08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update PR Newswire -5.52%
Mar-27-23 08:00AM	Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors PR Newswire
Mar-26-23 02:00PM	Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer PR Newswire
Mar-15-23 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update PR Newswire
Mar-03-23 08:00AM	Aadi Bioscience Announces Leadership Transition PR Newswire -14.51%
08:00AM	Loading…
Feb-22-23 08:00AM	Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference PR Newswire
Nov-17-22 08:00AM	Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting PR Newswire
Nov-09-22 08:00AM	Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update PR Newswire
Nov-08-22 04:00PM	Aadi Bioscience Announces Planned Leadership Transition PR Newswire
Nov-03-22 08:00AM	Aadi Bioscience to Present at Upcoming Investor Conferences PR Newswire
Oct-27-22 08:00AM	Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium PR Newswire
Oct-12-22 08:01AM	Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium PR Newswire
08:00AM	Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation PR Newswire
Sep-22-22 04:01PM	Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing PR Newswire
Sep-01-22 08:00AM	Aadi Bioscience Announces Participation in Upcoming September Investor Conferences PR Newswire
08:00AM	Loading…
Aug-10-22 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update PR Newswire
Aug-04-22 06:21AM	Is Aadi Bioscience, Inc. (NASDAQ:AADI) Popular Amongst Insiders? Simply Wall St.
Jul-28-22 08:30AM	Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update PR Newswire
Jun-23-22 08:00AM	Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes GlobeNewswire +6.00%
Jun-01-22 08:00AM	Aadi Bioscience to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-31-22 08:00AM	Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications GlobeNewswire
May-26-22 05:10PM	Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting GlobeNewswire +5.11%
May-18-22 07:00AM	Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire -7.91%
May-12-22 08:32AM	UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update GlobeNewswire +9.33%
07:00AM	Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update GlobeNewswire
May-09-22 08:00AM	Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders GlobeNewswire -10.81%
May-04-22 08:00AM	Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO from Centers for Medicare and Medicaid Services GlobeNewswire
Apr-28-22 05:07PM	Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022 GlobeNewswire
Apr-18-22 08:00AM	Aadi Bioscience to Participate at the Jefferies Biotech on the Bay Summit GlobeNewswire -5.81%
Apr-08-22 01:09PM	Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR) GlobeNewswire
05:13AM	Loading…
Apr-01-22 05:13AM	Top Biotech Stocks for Q2 2022 Investopedia
Mar-31-22 02:45PM	Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes GlobeNewswire
Mar-17-22 07:00AM	Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update GlobeNewswire +8.40%
Mar-01-22 07:00AM	Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowens 42nd Annual Health Care Conference GlobeNewswire
Feb-25-22 04:41AM	Here's What Aadi Bioscience, Inc.'s (NASDAQ:AADI) Shareholder Ownership Structure Looks Like Simply Wall St.
Feb-23-22 07:00AM	Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa GlobeNewswire
Jan-04-22 04:30PM	Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference GlobeNewswire
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... GuruFocus.com
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Nov-27-21 06:01AM	Companies Like Aadi Bioscience (NASDAQ:AADI) Are In A Position To Invest In Growth Simply Wall St.
06:01AM	Some Analysts Just Cut Their Aadi Bioscience, Inc. (NASDAQ:AADI) Estimates Simply Wall St.
Nov-23-21 04:22PM	Aadi Bioscience Pops And Then Tumbles After Snagging Its First FDA Approval Investor's Business Daily
06:00AM	Aadi Bioscience Announces FDA Approval of its First Product FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) GlobeNewswire
Nov-15-21 08:00AM	UPDATE Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) GlobeNewswire +7.31%
Nov-13-21 01:35PM	Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) GlobeNewswire
Nov-10-21 07:00AM	Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire -16.93%
Nov-09-21 08:00AM	Aadi Bioscience to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-01-21 04:05PM	Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer GlobeNewswire
Oct-25-21 08:00AM	Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer GlobeNewswire
Oct-22-21 08:00AM	Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology GlobeNewswire
Oct-19-21 05:22PM	Aadi Bioscience to Participate in H.C. Wainwrights 2nd Annual Precision Oncology Conference 2021 GlobeNewswire
Oct-06-21 08:00AM	Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Sep-20-21 08:30AM	Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer GlobeNewswire
Sep-13-21 08:00AM	Aadi Bioscience Appoints Emma Reeve to its Board of Directors GlobeNewswire

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience